कृपया अन्य खोज का प्रयास करें
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Stephen R. Biggar | 53 | 2015 | Independent Director |
G. Bradley Cole | 68 | 2020 | Independent Director |
Richard S. Levy | 66 | 2019 | Independent Director |
Tracey L. McCain | 56 | 2018 | Independent Director |
Thomas R. Malley | 55 | 2016 | Independent Director |
Felix James Baker | 55 | 2015 | Lead Independent Director |
Sanj K. Patel | 55 | 2015 | CEO & Chairman of the Board |
Barry D. Quart | 67 | 2015 | Independent Director |
Robert J. Desnick | - | - | Chairman of Scientific Advisory Board |
Kimberly J. Popovits | 65 | 2018 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है